Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuning Le

Showing results (171-180 of 179) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 179 results.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.
Nature Communications|November 18, 2021
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancerMing Chen, Runzhe Chen, Ying Jin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.
Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.
The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Nature|February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 18

Showing results (171-180 of 179) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 179 results.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.
Nature Communications|November 18, 2021
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancerMing Chen, Runzhe Chen, Ying Jin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.
Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.
The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Nature|February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 18